Provides drug discovery and development services, focusing on preclinical and clinical research solutions.
Inotiv, Inc. specializes in providing comprehensive nonclinical and analytical services crucial to drug discovery and development for pharmaceutical and medical device industries globally. Operating through two primary segments, Discovery and Safety Assessment (DSA), and Research Models and Services (RMS), Inotiv supports a wide array of research needs. The DSA segment focuses on scientific services such as computational toxicology, disease pharmacology, DMPK (drug metabolism and pharmacokinetics), safety pharmacology, and more. Meanwhile, the RMS segment is involved in the production and distribution of research models, specialized diets, bedding materials, and other bioproducts essential for preclinical studies.
Formerly known as Bioanalytical Systems, Inc., Inotiv rebranded in March 2021 to reflect its expanded capabilities and enhanced service offerings in the life sciences sector. Established in 1974 and headquartered in West Lafayette, Indiana, the company operates across the United States, North America, the Pacific Rim, Europe, and other international markets. Inotiv's expertise spans a broad range of disciplines including pathology services (such as histology and digital pathology), bioanalysis (covering both regulated and non-regulated bioanalysis), proteomics, and consulting services tailored to meet the specific demands of pharmaceutical research and development.
With a commitment to advancing scientific research and supporting regulatory compliance, Inotiv collaborates closely with pharmaceutical companies, academic institutions, government research centers, and medical research facilities. Its integrated approach combines cutting-edge technology, rigorous scientific expertise, and a deep understanding of regulatory requirements to accelerate the development of new therapeutics and medical devices, ultimately contributing to improved patient outcomes worldwide.